Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nifedipine + valsartan is a fixed-dose combination of two antihypertensive agents used for the management of high blood pressure (essential hypertension). Nifedipine is a dihydropyridine calcium channel blocker that works by inhibiting voltage-gated L-type calcium channels in vascular smooth muscle and myocardial cells, leading to vasodilation and reduced peripheral resistance. Valsartan is an angiotensin II receptor blocker (ARB) that blocks the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone-mediated volume expansion. The combination provides additive or synergistic blood pressure-lowering effects by targeting different pathways involved in vascular tone regulation. This therapy has been shown to be effective in achieving target blood pressure levels with a favorable safety profile[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nifedipine + valsartan.